Prana Biotech has always stated that their goals were...

Prana Biotech has always stated that their goals were NeuroDegenerative Diseases as well as Cataracts.

I have heard nothing from Prana that they are looking for a specific drug for Glaucoma or Cataracts and was wondering if their initial statement regarding Cataracts was because they were going after the issues with their PBT candidates as an aside.

If this is the case, I view it as a positive as in taking care of AB brain accumulation the drug would still be involved in cleaning the CSF drainage pathways/other build-up areas.

Inflammation seems the last area which could be affecting drainage (reduced CSF flow areas) as well as BBB cell clearances (other than lack of plasticity with aging).

Mr. Tanzi was all about the need for inflammation control at his NY lecture and we know PBT2 lessens inflammation by virtue of Neuronic health.

Mr. Tanzi making statements saying this is needed, does not necessarily mean PBT is not also tackling these issues!